Leber Congenital Amaurosis
8 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Retinal Diseases
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| AAV2-hRPE65v2,voretigene neparvovec-rzyl for leber congenital amaurosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brinretigene Vesgedparvovec for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 High Dose for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 High Dose + OCU400 Med Dose for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Low Dose for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Med Dose for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Second Eye Dosing for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| voretigene neparvovec-rzyl for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.